TY - CHAP
T1 - Patient-Specific Microfluidic Cancer Spheroid Cultures for Testing Cancer Therapies
AU - Choi, Daheui
AU - Gonzalez-Suarez, Alan M.
AU - Billadeau, Daniel D.
AU - Ma, Wen Wee
AU - Stybayeva, Gulnaz
AU - Revzin, Alexander
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023
Y1 - 2023
N2 - The field of oncology increasingly focuses on strategies to predict effectiveness of a given therapy on a patient-by-patient basis. Such precision or personalized oncology has the potential of significantly extending patient survival time. Patient-derived organoids are seen as the main source of patient tumor tissue that may be used for therapy testing in personalized oncology. The gold standard approach for culturing cancer organoids is in standard multi-well plates coated with Matrigel. Despite their effectiveness, these standard organoid cultures have drawbacks, namely, requirement of a large starting cell population and polydispersity of cancer organoid sizes. The latter drawback makes it challenging to monitor and quantify changes in organoid size in response to therapy. Microfluidic devices with integrated arrays of microwells may be used to both decrease the amount of starting cellular material required to form organoids and to standardize organoid size to make therapy assessment easier. Herein, we describe methodology for making microfluidic device as well as for seeding patient-derived cancer cells, culturing organoids, and testing therapies using these devices.
AB - The field of oncology increasingly focuses on strategies to predict effectiveness of a given therapy on a patient-by-patient basis. Such precision or personalized oncology has the potential of significantly extending patient survival time. Patient-derived organoids are seen as the main source of patient tumor tissue that may be used for therapy testing in personalized oncology. The gold standard approach for culturing cancer organoids is in standard multi-well plates coated with Matrigel. Despite their effectiveness, these standard organoid cultures have drawbacks, namely, requirement of a large starting cell population and polydispersity of cancer organoid sizes. The latter drawback makes it challenging to monitor and quantify changes in organoid size in response to therapy. Microfluidic devices with integrated arrays of microwells may be used to both decrease the amount of starting cellular material required to form organoids and to standardize organoid size to make therapy assessment easier. Herein, we describe methodology for making microfluidic device as well as for seeding patient-derived cancer cells, culturing organoids, and testing therapies using these devices.
KW - Cancer spheroids
KW - Chemotherapy
KW - Microfluidic cancer cultures
KW - Patient-derived organoids
KW - Personalized therapy
UR - http://www.scopus.com/inward/record.url?scp=85161668999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161668999&partnerID=8YFLogxK
U2 - 10.1007/978-1-0716-3271-0_15
DO - 10.1007/978-1-0716-3271-0_15
M3 - Chapter
C2 - 37300619
AN - SCOPUS:85161668999
T3 - Methods in Molecular Biology
SP - 219
EP - 231
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -